Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
View all Diseases
Topics
Diagnostics
Biology
Trial Updates
Treatment
Surgery
Prevention
View all Topics
Conferences
IHC 2021
ESOC 2021
IEC 2021
EAN 2021
AAN 2021
AD/PD 2021
View all Conferences
Features
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Headache
1:09
Migraine is one of the principal causes of disability worldwide
Susan Hutchinson
• 21 Apr 2021
2:06
The stigma of migraine in women’s life
Susan Hutchinson
• 21 Apr 2021
1:34
STOP 301: non-oral INP104 for the acute treatment of migraine
Jessica Ailani
• 18 Apr 2021
3:02
Atogepant meets all endpoints in the Phase III ADVANCE trial for episodic migraine prevention
Jessica Ailani
• 18 Apr 2021
1:06
Ubrogepant safety by age, gender and race
Jessica Ailani
• 18 Apr 2021
2:36
Rimegepant to treat acute migraine in patients with cardiovascular risk factors
Susan Hutchinson
• 21 Apr 2021
3:21
Update on the OVERCOME study
Susan Hutchinson
• 21 Apr 2021
3:02
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant
Jessica Ailani
• 18 Apr 2021
2:18
Comprehensive migraine update at AAN 2021
Jessica Ailani
• 18 Apr 2021
4:04
The importance of shared decision making in migraine
Jessica Ailani
• 18 Apr 2021
1:25
The unmet needs of migraine patients
Jessica Ailani
• 26 Oct 2020
5:26
Long-term intermittent use of ubrogepant to treat acute migraines
Jessica Ailani
• 26 Oct 2020
11:31
Therapeutic landscape for cluster headache
Stewart Tepper
• 24 May 2020
2:09
Challenges in migraine management
Uwe Reuter
• 22 May 2020
20:54
CGRP monoclonal antibodies & migraine management during COVID-19 pandemic
Stewart Tepper
• 24 May 2020
4:14
BKCa channels: potential novel anti-migraine target
Messoud Ashina
• 29 May 2020
Previous
1
2
3
4
5
6
Next
